ZEISS at EMO Hannover 2025

Experience some of the most exciting highlights from our ZEISS product portfolio.

From lab to patient – the art of developing new antibody therapies

For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...

Studie: Protein i urinen en biomarkör för demensrisk

Höga nivåer av proteinet albumin i urinen indikerar en ökad risk för att utveckla demens, enligt en stor studie från Karolinska institutet, KI.

Achieve Effortless, Standardized Automation with the new ZEISS Automation Interface

Simple interfaces for automated loading of CMMs.

New drug to simplify treatment of hemophilia

A new type of treatment for hemophilia, which only needs to be administered every two months, has been approved by the U.S. Food and Drug Administration (FDA).

Charged with illegal pharmaceutical sales – alleged earnings of 23 million

For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Söder...

Explore the possibilities of the new ZEISS METROTOM 800 320 kV

Free ZEISS webinar July 10, 9:00-9:45 AM and 5:00-5:45 PM.

Final assembly inspection of medical plastics

Technical paper by ZEISS Medical Industry Solutions.

”The importance of stratification in a statistician’s August kitchen”

Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.

Discover ZEISS ZEN core – now for electron microscopy

Watch the recording of our free webinar.

Genmab to Acquire Dutch biotech for USD 8 Billion

Danish pharmaceutical company Genmab has agreed to acquire Dutch firm Merus, a developer of cancer therapies, for USD 8 billion, equivalent to nearly SEK 75 billion.

New moves around Nykode's management – withdrawal of resignations

Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2025)

Enkelt test kan förutsäga leversjukdom - ”Bygger på tre enkla blodprover”

Ett blodtest, utvecklat av forskare vid Karolinska institutet, kan förutsäga risken att utveckla allvarlig leversjukdom, enligt en ny studie

The Covid pandemic accelerated the development of cancer vaccine

The Covid pandemic gave a major boost to the vaccine field. The Danish biotech company Expres2ion Biotechnologies, which is developing a vaccine against breast ...

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

The top five most expensive drugs in 2025

New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...

Eli Lilly requests re-examination of Alzheimer's drug recommendation

Eli Lilly has requested that the EMA re-examine its opinion on the company's Alzheimer's drug, Kisunla, the agency announced on Friday.

Nytt blodtest ger hopp om diagnosmetod för ME

Ett nytt blodtest visar lovande resultat för att kunna upptäcka ME/CFS, enligt en brittisk studie. Resultaten väcker hopp om en framtida biomarkör, men metoden ...

BMS and venture capital giant form new company

The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company wil...

Allogene discontinues investigational antibody following patient death

U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pi...

The investor: “The major common diseases are hot again”

She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...

Han är ny vd för Atrogi – ska ta obesitaskandidat till nästa fas

Det svenska bioteknikbolaget Atrogi, som utvecklar en oral kandidat mot obesitas, har utsett Paul Little till ny vd med omedelbar verkan.

Quality assurance for research and development of medical devices

Overcome the hurdles of research, development, and QA lab environments within the regulated medical technology industry.